心臓の患者における心不全の予防 心臓の患者における心不全の予防 評価 (HOPE) 試験
J Malcolm O Arnold1, Salim Yusuf, James Young
1London Health Sciences Centre, London, Canada. malcolm.arnold@lhsc.on.ca
Circulation
|March 12, 2003
まとめ
ACE阻害剤であるラミプリルは,高リスクの個人に新たに発症した心不全を効果的に予防します. この心臓血管薬は,心不全の発症率を大幅に低下させ,患者のアウトカムを改善します.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
背景:
- 以前の心不全予防試験は,低射出分数または高血圧の患者に焦点を当てていました.
- この研究では,低射出分数または心不全が既にある高リスクの個体における心不全を予防するラミプリルの有効性を調査しました.
研究 の 目的:
- 血管新生変換酵素 (ACE) 阻害剤であるラミプリルの心不全の発症を予防する効果を評価する.
- 高リスク集団における心血管疾患へのラミプリルの影響を評価する.
主な方法:
- ラミプリル (毎日10mg) またはプラセボを4.5年間投与された9297人の患者が参加したダブルブラインド,ランダム化試験です.
- 心不全の発達,心血管疾患,死亡率のモニタリング.
主要な成果:
- ラミプリルは,新規発症の心不全率を11.5%から9.0%に大幅に低下させた (相対リスク,0.77;P<0.0001).
- 心不全のリスクを増加させる要因には,冠動脈疾患,マイクロアルブミヌーリア,左心室縮症,高齢化,糖尿病などがある.
- ラミプリルは,前回の心筋梗塞を患った患者および未患者を含むサブグループ全体で一貫した利点を示し,高出血圧の患者でより大きな効果を示しました.
結論:
- ラミプリルは,高リスクの心血管疾患患者の新規発症した心不全の発生率を著しく低下させます.
- この発見は,リスク集団における心不全を予防するためにラミプリルの使用を支持する.
さらに関連する動画
04:20Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
Published on: October 1, 2019
07:49A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
Published on: July 21, 2023
関連する概念動画
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...